Copyright
©The Author(s) 2015.
World J Gastroenterol. May 7, 2015; 21(17): 5352-5358
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5352
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5352
Figure 1 Rate of gastrointestinal perforation.
Figure 2 Progression-free survival (A) and overall survival (B) in the MAX trial patients with peritoneal disease: chemotherapy and bevacizumab vs chemotherapy alone.
Chemo: Chemotherapy; Bev: Bevacizumab.
- Citation: Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World J Gastroenterol 2015; 21(17): 5352-5358
- URL: https://www.wjgnet.com/1007-9327/full/v21/i17/5352.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i17.5352